Manufacturers & suppliers
B2B · supplies businessesThe upstream B2B peptide supply chain — the companies that make the active ingredient at scale and sell to businesses, not individuals. To find a retail seller with independent test grades, see Vendors →
Pharma-grade CDMOs
GMP contract makers that supply regulated pharmaceutical companies (Western & Japanese).
The largest independent peptide & oligonucleotide CDMO. GMP/cGMP in Switzerland & the US; routinely FDA/EMA/Swissmedic/PMDA-inspected; states ISO 9001 & 13485 and EDQM (CEP) certificates. Publicly traded (SIX: BANB).
Global CDMO with six cGMP facilities across Europe, the US and India; states 1,000+ GMP peptides produced, with notable GLP-1/metabolic exposure. Listed (SIX: PPGN).
cGMP peptide-API CDMO; both sites FDA-inspected multiple times. Solid-phase to 1,000L, solution-phase to 5,000L.
Announced for acquisition by CordenPharma (May 2026) — pending close.
Full-service CDMO, ~11 inspected cGMP facilities across Europe & N. America; peptides a core platform (incl. proprietary TAPS). Expanding peptide capacity (~$1B).
Large global CDMO; peptides are one platform alongside small molecules, HPAPIs, biologics and bioconjugates at Visp. States facilities certified to applicable cGMP standards.
GMP peptide APIs via SPPS/LPPS, incl. long/complex peptides; company states MHRA-inspected. A 2024 facility reportedly more than doubled peptide-API capacity.
Long-established peptide CDMO (cGMP + non-GMP): custom peptides, fragments, amino-acid derivatives. Now owned by Granules India (acquisition reported closed 2025).
Biosynth (Peptide Division)
B2BSwitzerland (Staad) + NL/UK · est. peptide division 2022biosynth.com ↗Custom & catalog peptides through multi-kilogram GMP synthesis + fill-finish; built via roll-up of vivitide, Pepscan and Pepceuticals.
GMP custom peptide synthesis (30+ yrs) plus mRNA/vaccine/biologics CDMO. Company states it is FDA-inspected and ISO 9001/13485 certified. Part of Kaneka (Japan).
Established small-molecule API CDMO expanded into GMP peptides (SPPS/LPPS), early-clinical through large scale.
Technology-driven peptide/oligonucleotide CDMO (GMP, lab → commercial). Reaches Western customers via Nagase's distribution channel.
Research-grade & custom synthetic peptides (Fmoc SPPS) in ISO-9001 facilities; its Patheon CDMO is mainly small-molecule/biologics. Not a large commercial peptide-API peer of the above.
Peptide-API makers (Asia)
The upstream peptide-API capacity (China, Korea, Taiwan) that underlies much of the global market, including the GLP-1 class. Credentials are largely company-stated; we don't imply any maker sells into illicit channels.
Large-scale GMP peptide APIs incl. the GLP-1 class (semaglutide, liraglutide) plus oligonucleotides; company states FDA-inspected and EDQM-recognized facilities. ~20–30 t/yr.
Among the largest peptide-CDMO capacities globally (20+ SPPS lines); regulated clinical & commercial supply.
Subject to US 'BIOSECURE'-style geopolitical scrutiny — developing context, not settled fact.
Peptide APIs + CDMO + cosmetic peptides; company reports US-DMF filings (liraglutide, bivalirudin, octreotide…) and ~25 cGMP lines.
One of China's largest peptide-API bases (ton-scale); company claims NMPA/FDA/EDQM GMP recognition. Publicly listed.
GLP-1-focused peptide APIs (semaglutide, tirzepatide, liraglutide) plus custom synthesis. Regulator-recognition claims are vendor-stated and not independently verified.
Pharmaceutical & cosmetic peptides, custom synthesis and HPLC purification; claims ISO 9001 and GMP-standard clean rooms (company-stated).
Reported as Korea's first GMP-certified peptide raw-material maker (MFDS); GMP, custom and catalog peptide raw materials. KOSDAQ-listed.
API maker incl. peptides plus small molecules; sites stated to comply with FDA and international GMP. Regulated-market focus.
Maker + sells direct
Companies that both manufacture and sell their peptides directly — to labs and researchers (B2B), not to consumers.
cGMP peptide/API CDMO AND a leading maker of large-scale automated peptide synthesizers used by other CDMOs. Company reports an FDA recommendation-for-approval for Exenatide API.
GMP peptide & oligonucleotide APIs AND research/catalog peptides + Fmoc amino acids; company reports multiple FDA inspections and a 2024 TGA inspection. Subsidiary of Medtide (HKEX, 2025).
Custom & catalog research peptides (microwave SPPS) sold direct to 10,000+ scientists, plus a GMP/CDMO line (ProBio). States ISO 9001/13485 quality systems.
Makes research peptides in-house plus custom synthesis, antibodies and assay kits (7,000+ products). B2B to researchers — explicitly not to the general public.
Custom & catalog research peptides (mg → multi-kg, ~98%) sold direct to labs; claims ISO 9001 (research-grade, not a verified GMP API maker).
Wholesale & white-label suppliers
Bulk B2B and private-label platforms that power multiple retail storefronts. Buyer-beware: 'cGMP' or 'Made in USA' here often refers to an unnamed third-party manufacturer or repackaged imported powder.
Major upstream supplier of Fmoc amino acids, coupling reagents and resins plus very high-volume custom research peptides — the building-block backbone many downstream synthesizers and shops depend on.
Research-grade catalog + custom + bulk/white-label (custom-labeled vials). Claims third-party COAs and ISO-compliant facilities (self-asserted).
White-label/private-label platform: 60+ research peptides with dropship, branding and storefront for resellers. Its cGMP claim refers to an unnamed third-party manufacturer.
Intermediary — does not manufacture; coordinates 'cGMP research-manufacturing partners,' white-label sourcing and dropship for new peptide brands.
3PL / private-label fulfillment (warehousing, cold-chain, blind dropship) for branded peptide storefronts — the plumbing that lets one backend power many brands. No GMP claim.